ATTORNEY PROFILES

Jeffrey Kodroff

Jeffrey Kodroff

Of Counsel

P: 215-496-0300
E: jkodroff@srkattorneys.com

Bar Admissions

Pennsylvania, 1989
U.S. District Court Middle District of Pennsylvania
U.S. District Court Eastern District of Pennsylvania
U.S. Federal Courts, 1989

Education

J.D. Temple University School of Law
Philadelphia, Pennsylvania, 1989

B.S. La Salle University
Philadelphia, Pennsylvania, 1986

Honors: Magna Cum Laude
Major: Finance

Professional Associations and Memberships

Pennsylvania Bar Association
Philadelphia Bar Association
American Bar Association
Bureau of National Affairs Class Action Litigation Report
Member, Advisory Board

JEFFREY L. KODROFF

Jeffrey is focused on leading pioneering litigation involving healthcare, antitrust and consumer issues.  He was among the first attorneys to bring  class action litigation against national health maintenance organizations. See Tulino v. U.S. Healthcare, Inc., No. 95-CV-4176 (E.D. Pa.).  He also filed the first class action complaint and led the  litigation against manufacturers of cancer drugs relating to the illegal marketing practices and use of the published Average Wholesale Price.  See In re Lupron Marketing and Sales Practices Litigation, MDL No. 1430 (D. Mass.), which settled for $150 million.  Mr. Kodroff was also co-lead counsel in a consolidated national class action against many of the largest pharmaceutical companies in the world, including GlaxoSmithKline, BMS, J&J, Schering-Plough and AstraZeneca, for their illegal marketing and use of a false Average Wholesale Price. See In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456 (D. Mass.), which settled for over $300 million.

He was also lead counsel in a massive class action against pharmaceutical wholesaling giant McKesson Corporation and pharmaceutical pricing publishers First DataBank, Inc. and Medi-Span. The case addressed an unlawful conspiracy to  mark-up in the Average Wholesale Prices (“AWPs”) of hundreds of drugs, causing consumers and insurers to substantially overpay. New England Carpenters Health Benefits Fund v. First Databank, Inc. and McKesson Corp., C.A. 05-11148  (D. Mass.); and District 37 Health and Securities Fund v. Medi-Span, C.A. No. 07-10988 (D. Mass. 2007).  This litigation settled for $350 million plus an agreement to roll back AWPs by 5% thereby saving the Class and others additional hundreds of millions of dollars.

Mr. Kodroff is very active in fighting brand named pharmaceutical companies’ attempts to keep generic drugs off the market.  Mr. Kodroff has served or is serving as a lead counsel in many of these “generic suppression” cases, including:

  • Stop & Shop Supermarket Co. v. Smithkline Beecham Corp. C.A. 03-4578 (E.D. Pa.) (settled for $150 million)
  • In Re Suboxone Antitrust Litigation, 2:13-md-02445-MSG (E.D. Pa.)
  • In re Effexor Antitrust Litigation, 11-cv- 05590 (D.N.J.)
  • In Re Celebrex Antitrust Litigation, Case No. 14-cv-361(E.D. Va.)
  • In re Niaspan Antitrust Litigation, MDL No. 2460 (E.D. Pa.)
  • In re Express Scripts, Inc., PBM Litigation, Master Case No. 05-md-01672-SNL (E.D. Mo.)
  • In re Lovenox Antitrust Litigation, Case No. CV05-5598 (C.D. Cal.)
  • In re DDAVP Indirect Purchaser Antitrust Litigation, Case No. 05 Civ. 2237 (S.D.N.Y.)
  • In re: Merck Mumps Vaccine Antitrust Litigation, Master File No. 2:12-cv-03555 (E.D. Pa.)
  • Vista Healthplan Inc. v. Cephalon, Inc., et al., Case No. 2:06-cv-1833 (E.D. Pa.) (Provigil)

Beyond pharmaceuticals, Mr. Kodroffis leadinga significant privacy case arising out of Google’s interception of electronic communications by its Street View vehicles.  In re Google Inc. Street View Electronic Communications Litigation, Case No. C 10-md-02184 JW (N.D. Cal.). In a major victory for plaintiffs and consumer privacy rights, the 9th Circuit Court of Appeals agreed with plaintiffs’  interpretation of the federal Wire Tap Act and affirmed the District Court’s refusal to dismiss the action.

Mr. Kodroff has also been lead counsel in many class action securities fraud cases, including In re Unisys Corporation Securities Litigation, No. 99-CV-5333 (E.D. Pa.); In re Dreyfus Aggressive Growth Mutual Fund Litigation, No. 98 Civ. 4318 (HB) (S.D.N.Y.); Kalodner v. Michaels Stores, Inc., No. 3:95-CV-1903-R (N.D. Tex.); In re Valuevision International, Inc. Securities Litigation, Master File No. 94-CV-2838 (E.D. Pa.); In re GTECH Holdings Corp. Securities Litigation, Master File No. 94-0294 (D.R.I.); In re Surgical Laser Technologies, Inc. Securities Litigation,  No. 91-CV-2478 (E.D. Pa.); and The Berwyn Fund v. Kline, No. 4671-S-1991 (Dauphin Cty. C.C.P.).

Mr. Kodroff is  a Continuing Legal Education presenter on class actions and health care issues and has made presentations at conferences including the NCPERS Health Care Symposium and the Pennsylvania Public Employees Retirement System Conference. He was also selected by “Who’s Who Legal: Competition” as one of the world’s leading competition practitioners and by Lawdragon as one of the leading Plaintiff Financial Lawyers in the country.

He also serves on the advisory board for the Bureau of National Affairs Class Action Litigation Report. He has  appeared with one of his clients before the U.S. House of Representatives, Subcommittee on Housing and Community Opportunity, Committee on Banking and Financial Services on the issue of predatory lending.

Mr. Kodroff is AV-rated by Martindale-Hubbell.

Jeffrey Kodroff

Partner
P: 215-496-0300
E: jkodroff@srkattorneys.com

JEFFREY L. KODROFF

Jeffrey is focused on leading pioneering litigation involving healthcare, antitrust and consumer issues.  He was among the first attorneys to bring  class action litigation against national health maintenance organizations. See Tulino v. U.S. Healthcare, Inc., No. 95-CV-4176 (E.D. Pa.).  He also filed the first class action complaint and led the  litigation against manufacturers of cancer drugs relating to the illegal marketing practices and use of the published Average Wholesale Price.  See In re Lupron Marketing and Sales Practices Litigation, MDL No. 1430 (D. Mass.), which settled for $150 million.  Mr. Kodroff was also co-lead counsel in a consolidated national class action against many of the largest pharmaceutical companies in the world, including GlaxoSmithKline, BMS, J&J, Schering-Plough and AstraZeneca, for their illegal marketing and use of a false Average Wholesale Price.  See In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456 (D. Mass.), which settled for over $300 million.)

He was also  lead counsel in a massive class action against pharmaceutical wholesaling giant McKesson Corporation and pharmaceutical pricing publishers First DataBank, Inc. and Medi-Span. The case addressed an unlawful conspiracy to  mark-up in the Average Wholesale Prices (“AWPs”) of hundreds of drugs, causing consumers and insurers to substantially. overpay. New England Carpenters Health Benefits Fund v. First Databank, Inc. and McKesson Corp., C.A. 05-11148  (D. Mass.); and District 37 Health and Securities Fund v. Medi-Span, C.A. No. 07-10988 (D. Mass. 2007).  This litigation settled for $350 million plus an agreement to roll back AWPs by 5% thereby saving the Class and others additional hundreds of millions of dollars.

Learn More

Mr. Kodroff is  very active in fighting brand named pharmaceutical companies’ attempts to keep generic drugs off the market.  Mr. Kodroff has served or is serving as a lead counsel in many of these “generic suppression” cases, including:

  • Stop & Shop Supermarket Co. v. Smithkline Beecham Corp. C.A. 03-4578 (E.D. Pa.) (settled for $150 million)
  • In Re Suboxone Antitrust Litigation, 2:13-md-02445-MSG (E.D. Pa.)
  • In re Effexor Antitrust Litigation, 11-cv- 05590 (D.N.J.)
  • In Re Celebrex Antitrust Litigation, Case No. 14-cv-361(E.D. Va.)
  • In re Niaspan Antitrust Litigation, MDL No. 2460 (E.D. Pa.)
  • In re Express Scripts, Inc., PBM Litigation, Master Case No. 05-md-01672-SNL (E.D. Mo.)
  • In re Lovenox Antitrust Litigation, Case No. CV05-5598 (C.D. Cal.)
  • In re DDAVP Indirect Purchaser Antitrust Litigation, Case No. 05 Civ. 2237 (S.D.N.Y.)
  • In re: Merck Mumps Vaccine Antitrust Litigation, Master File No. 2:12-cv-03555 (E.D. Pa.)
  • Vista Healthplan Inc. v. Cephalon, Inc., et al., Case No. 2:06-cv-1833 (E.D. Pa.) (Provigil)

Beyond pharmaceuticals, Mr. Kodroffis leadinga significant privacy case arising out of Google’s interception of electronic communications by its Street View vehicles.  In re Google Inc. Street View Electronic Communications Litigation, Case No. C 10-md-02184 JW (N.D. Cal.), which. .  In a major victory for plaintiffs and consumer privacy rights, the 9th Circuit Court of Appeals agreed with plaintiffs’  interpretation of the federal Wire Tap Act and affirmed the District Court’s refusal to dismiss the action.

Mr. Kodroff has also been lead counsel in many class action securities fraud cases, including In re Unisys Corporation Securities Litigation, No. 99-CV-5333 (E.D. Pa.); In re Dreyfus Aggressive Growth Mutual Fund Litigation, No. 98 Civ. 4318 (HB) (S.D.N.Y.); Kalodner v. Michaels Stores, Inc., No. 3:95-CV-1903-R (N.D. Tex.); In re Valuevision International, Inc. Securities Litigation, Master File No. 94-CV-2838 (E.D. Pa.); In re GTECH Holdings Corp. Securities Litigation, Master File No. 94-0294 (D.R.I.); In re Surgical Laser Technologies, Inc. Securities Litigation,  No. 91-CV-2478 (E.D. Pa.); and The Berwyn Fund v. Kline, No. 4671-S-1991 (Dauphin Cty. C.C.P.).

Mr. Kodroff is  a Continuing Legal Education presenter on class actions and health care issues and has made presentations at conferences including the NCPERS Health Care Symposium and the Pennsylvania Public Employees Retirement System Conference.

He also serves on the advisory board for the Bureau of National Affairs Class Action Litigation Report. Hehas  appeared with one of his clients before the U.S. House of Representatives, Subcommittee on Housing and Community Opportunity, Committee on Banking and Financial Services on the issue of predatory lending.

Mr. Kodroff is a resident of Dresher, Pennsylvania.  Mr. Kodroff is AV-rated by Martindale-Hubbell.

Jeffrey Kodroff

Partner
P: 215-496-0300
E: jkodroff@srkattorneys.com

JEFFREY L. KODROFF

Jeffrey is focused on leading pioneering litigation involving healthcare, antitrust and consumer issues.  He was among the first attorneys to bring  class action litigation against national health maintenance organizations. See Tulino v. U.S. Healthcare, Inc., No. 95-CV-4176 (E.D. Pa.).  He also filed the first class action complaint and led the  litigation against manufacturers of cancer drugs relating to the illegal marketing practices and use of the published Average Wholesale Price.  See In re Lupron Marketing and Sales Practices Litigation, MDL No. 1430 (D. Mass.), which settled for $150 million.  Mr. Kodroff was also co-lead counsel in a consolidated national class action against many of the largest pharmaceutical companies in the world, including GlaxoSmithKline, BMS, J&J, Schering-Plough and AstraZeneca, for their illegal marketing and use of a false Average Wholesale Price.  See In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456 (D. Mass.), which settled for over $300 million.)

He was also  lead counsel in a massive class action against pharmaceutical wholesaling giant McKesson Corporation and pharmaceutical pricing publishers First DataBank, Inc. and Medi-Span. The case addressed an unlawful conspiracy to  mark-up in the Average Wholesale Prices (“AWPs”) of hundreds of drugs, causing consumers and insurers to substantially. overpay. New England Carpenters Health Benefits Fund v. First Databank, Inc. and McKesson Corp., C.A. 05-11148  (D. Mass.); and District 37 Health and Securities Fund v. Medi-Span, C.A. No. 07-10988 (D. Mass. 2007).  This litigation settled for $350 million plus an agreement to roll back AWPs by 5% thereby saving the Class and others additional hundreds of millions of dollars.

Learn More

Mr. Kodroff is  very active in fighting brand named pharmaceutical companies’ attempts to keep generic drugs off the market.  Mr. Kodroff has served or is serving as a lead counsel in many of these “generic suppression” cases, including:

  • Stop & Shop Supermarket Co. v. Smithkline Beecham Corp. C.A. 03-4578 (E.D. Pa.) (settled for $150 million)
  • In Re Suboxone Antitrust Litigation, 2:13-md-02445-MSG (E.D. Pa.)
  • In re Effexor Antitrust Litigation, 11-cv- 05590 (D.N.J.)
  • In Re Celebrex Antitrust Litigation, Case No. 14-cv-361(E.D. Va.)
  • In re Niaspan Antitrust Litigation, MDL No. 2460 (E.D. Pa.)
  • In re Express Scripts, Inc., PBM Litigation, Master Case No. 05-md-01672-SNL (E.D. Mo.)
  • In re Lovenox Antitrust Litigation, Case No. CV05-5598 (C.D. Cal.)
  • In re DDAVP Indirect Purchaser Antitrust Litigation, Case No. 05 Civ. 2237 (S.D.N.Y.)
  • In re: Merck Mumps Vaccine Antitrust Litigation, Master File No. 2:12-cv-03555 (E.D. Pa.)
  • Vista Healthplan Inc. v. Cephalon, Inc., et al., Case No. 2:06-cv-1833 (E.D. Pa.) (Provigil)

Beyond pharmaceuticals, Mr. Kodroffis leadinga significant privacy case arising out of Google’s interception of electronic communications by its Street View vehicles.  In re Google Inc. Street View Electronic Communications Litigation, Case No. C 10-md-02184 JW (N.D. Cal.), which. .  In a major victory for plaintiffs and consumer privacy rights, the 9th Circuit Court of Appeals agreed with plaintiffs’  interpretation of the federal Wire Tap Act and affirmed the District Court’s refusal to dismiss the action.

Mr. Kodroff has also been lead counsel in many class action securities fraud cases, including In re Unisys Corporation Securities Litigation, No. 99-CV-5333 (E.D. Pa.); In re Dreyfus Aggressive Growth Mutual Fund Litigation, No. 98 Civ. 4318 (HB) (S.D.N.Y.); Kalodner v. Michaels Stores, Inc., No. 3:95-CV-1903-R (N.D. Tex.); In re Valuevision International, Inc. Securities Litigation, Master File No. 94-CV-2838 (E.D. Pa.); In re GTECH Holdings Corp. Securities Litigation, Master File No. 94-0294 (D.R.I.); In re Surgical Laser Technologies, Inc. Securities Litigation,  No. 91-CV-2478 (E.D. Pa.); and The Berwyn Fund v. Kline, No. 4671-S-1991 (Dauphin Cty. C.C.P.).

Mr. Kodroff is  a Continuing Legal Education presenter on class actions and health care issues and has made presentations at conferences including the NCPERS Health Care Symposium and the Pennsylvania Public Employees Retirement System Conference.

He also serves on the advisory board for the Bureau of National Affairs Class Action Litigation Report. Hehas  appeared with one of his clients before the U.S. House of Representatives, Subcommittee on Housing and Community Opportunity, Committee on Banking and Financial Services on the issue of predatory lending.

Mr. Kodroff is a resident of Dresher, Pennsylvania.  Mr. Kodroff is AV-rated by Martindale-Hubbell.

Bar Admissions

Pennsylvania, 1989
U.S. District Court Middle District of Pennsylvania
U.S. District Court Eastern District of Pennsylvania
U.S. Federal Courts, 1989

Education

J.D. Temple University School of Law
Philadelphia, Pennsylvania, 1989

B.S. La Salle University
Philadelphia, Pennsylvania, 1986

Honors: Magna Cum Laude
Major: Finance

Professional Associations and Memberships

Pennsylvania Bar Association
Philadelphia Bar Association
American Bar Association
Bureau of National Affairs Class Action Litigation Report
Member, Advisory Board